Jobs
View more job listings or post a job
UC Davis - Equine Analytical Chemistry Program LC/MS CONFIRMATION SUPERVISOR (LABORATORY RESEARCH SUPERVISOR 2)  
Jazz Pharmaceuticals Head of Toxicology
Dow Development Laboratories Formulation Chemist
Genentech Scientist, DMPK
Pliant Therapeutics, Inc. Associate Director/ Director, Formulation Development
AbVision Inc. Research Scientist (Immunology/Cell Biology, all levels available)
Regulus Therapeutics Senior Research Associate/Scientist, Drug Metabolism and Pharmacokinetics
Aligos Therapeutics Principal Research Scientist, DMPK
Post a job

Symposium

Promising Therapeutic Approaches and Translational Medicine to Advance Novel Therapeutics (A Joint Symposium by PBSS and Stanford SPARK Program)


Speakers:
Organizers: Kevin Grimes (Stanford), Shichang Miao (ChemoCentryx), Snow Ge (Nektar), Greg Wagner
Date: 2019-03-07
Time: 8:45-17:00 Pacific Time
Registration fee (USD): Regular: $195; Academic: $50; Students/Postdocs & Unemployed: $20
Location: Crowne Plaza, Foster City, CA
Major Sponsor:
Vendor show vendors registered to date: (9)Applied StemCell; Averica Discovery Services; MagArray; Medpace; Novogene Corporation; Pacific BioLabs; PeproTech Inc; PHC former Panasonic Healthcare; R&D Systems
Registration: http://www.PBSS.org
Registration deadline:2019-03-05  (it will close sooner if the seating cap is reached)

About the Topic

This joint symposium between PBSS and the Stanford SPARK translational research program will review how industry and academia can work together to successfully translate academic research into commercial opportunities and will present examples of current and past SPARK projects. 

Academics often make promising discoveries that could lead to novel therapeutics, but lack the expertise to advance their science to a stage here commercial partners would be interested. The Stanford SPARK program is a collaboration between academic scientists and individuals from the local biopharmaceutical community who are willing to share their knowledge and expertise. SPARK is now in its twelfth year and nearly 50% of projects completing the program have been transferred to commercial partners. An additional 10% have entered investigator-initiated clinical trials. 


Agenda:
 

8:45- 8:55           Welcome Remarks (Shichang Miao, Kevin Grimes)

8:55- 9:30           Introduction to the Stanford SPARK Translational Research Program and Overview of Drug Discovery in the Academic Setting (Kevin Grimes, Professor, Co-Director of SPARK, Stanford)

9:30- 10:05         Peptide therapeutics for heart failure (or for Huntington's disease) (Daria Mochly-Rosen, Professor, Co-Director of SPARK, Stanford)

10:05-10:40        myc animal models and two therapeutic projects (Dean Felsher, Professor, Stanford)

10:40- 11:00       Break

11:00- 11:35       New treatment for dementia (Mehrdad Shamloo, Professor, Stanford)

11:35- 12:10       Antivirals targeting the host  (Shirit Einav, Professor, Stanford)

12:10- 1:00         Lunch

1:00- 1:35           Genomically-modfied cell therapies for IPEX syndrome (Rosa Bacchetta, Professor, Stanford)

1:35- 2:10           Drug target overview and selection: from the industry perspective (Nancy Pryer, Chief Development Officer, Nurix)

2:10- 2:45           Clinical candidate selection (John Link, VP  Medchem, Gilead)

2:45- 3:00           Break

3:00- 3:35           Funding for startups: seed/angel/VC funding and non-dilutive funding such as SBIR (Keith Wycoff, VP Research, Planet Biotechnology)

3:35- 4:10           GMP overview for small and/or large molecules (Kenneth Matthews, Gilead)

4:10- 4:45           IP considerations when starting a company: Avoid the Pitfalls and Set for Success (Janet Xiao, Partner, Morrison Foerster)

4:45- 5:15           Panel Discussion


2019-07-26, Generating Efficacious Enzyme Therapeutics based on Knowledge Learned From Biocatalytic Pharmaceutical Manufacture
2019-09-13, Biotransformation and Disposition of Larger Molecules: Peptides, Nucleotides, Proteins, mAbs, and ADCs
2019-10-03, Small-Molecule Bioanalytical Method Validation & Regulated Bioanalysis: Fundamentals, the New FDA Guidance and Regulatory Trends
2019-10-18, Physiologically Based Pharmacokinetic (PBPK) Modeling: Fundamentals, Regulatory Guidance & Applications
2019-11-12, Antibody Drug Discovery and Development: Hit Generation, Engineering, Cell-line Development, IND enabling studies, and Biosimilars
2019-12-10, In Vitro Diagnostics, Companion Diagnostics and Precision Medicine
2020-02-11, Drug-Device Combination
2020-05-12, Regulated Large Molecule Bioanalysis: Fundamentals, the New FDA Guidance and Beyond
2020-05-22, No More Undruggables: Unconventional Approaches for Drug Discovery and Design - prodrugs, PROTACS, fragment-based design, directed evolution and beyond
┬ęPharmaceutical & BioScience Society, International; Last Modified: 7/22/2019; Visited: 359; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

XCELERATE at Biotech Week Boston Driving the Future of the Life Science Industry. Sept. 11 at BCEC. Learn more.
UC Davis UC Davis LC/MS Confirmation Supervisor (Lab Rsch Supv 2) Apply Online: http://50.73.55.13/counter.php?id=165482 UC Davis is an AA/EOE
Hypha Discovery mg-g scale synthesis/purification of CYP/non-CYP metabolites including glucuronides. Plus NEW PolyCYPs kits for in-house synthesis of CYP metabolites.
BIOTECH WEEK BOSTON - Sept. 9-12 Access over 5,000 of the most innovative scientific minds & business leaders in Boston and around the world. Learn More.
Pacific BioLabs CRO in Bay Area - PK, toxicology, biocompatibility, analytical chemistry, immunogenicity, biomarker analysis, stability studies, sterility, endotoxin
Submit a Text Ad